CA2353839A1 - Derives de methotrexate - Google Patents

Derives de methotrexate Download PDF

Info

Publication number
CA2353839A1
CA2353839A1 CA002353839A CA2353839A CA2353839A1 CA 2353839 A1 CA2353839 A1 CA 2353839A1 CA 002353839 A CA002353839 A CA 002353839A CA 2353839 A CA2353839 A CA 2353839A CA 2353839 A1 CA2353839 A1 CA 2353839A1
Authority
CA
Canada
Prior art keywords
mtx
group
compound
methotrexate
gtp3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002353839A
Other languages
English (en)
Inventor
Robert George Whittaker
Xanthe E. Wells
Wayne Gerrard Reilly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth Scientific and Industrial Research Organization CSIRO
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2353839A1 publication Critical patent/CA2353839A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des conjugués de méthotrexate représentés par la formule I, ainsi que leur utilisation pour le traitement d'une maladie présentant une composante auto-immune et de cancers. Un exemple spécifique d'un composé représenté par la formule I consiste en méthotrexate-.gamma.-glycine Tris; dans laquelle M représente méthotrexate ou un de ses analogues; A=H, CX¿2?-O-R¿2? ou halogène; B=H, CX¿2?-O-R¿3? ou halogène; X représente indépendammen t H ou halogène; n est 0 ou égal ou supérieur à 1; Y représente un groupe de liaison, et si n est supérieur à 1, chaque Y est semblable ou différent; R¿1?, R¿2? et R¿3? sont semblables ou différents et représentent hydrogène, méthyle substitué ou non substitué, éthyle, ou un groupe acyle gras saturé ou insaturé, à condition que, quand n est 0 ou 1, et A représente CH¿2?-O-R¿2? et/ou B représente CH¿2?-O-R¿3?, alors R¿1?, R¿2? et R¿3? ne sont pas sélectionnés dans un groupe acyle gras; à condition que, quand n est supérieur ou égal à 2 et A représente CH¿2?-O-R¿2? et/ou B représente CH¿2?-O-R¿3? et au moins un de R¿1?, R¿2? et R¿3? représente un groupe acyle gras, -[Y]¿n?- est différent de -(AA)¿n-1?-, dans laquelle AA représente un acide aminé.
CA002353839A 1998-12-04 1999-12-03 Derives de methotrexate Abandoned CA2353839A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP7513A AUPP751398A0 (en) 1998-12-04 1998-12-04 Methotrexate derivatives
AUPP7513 1998-12-04
PCT/AU1999/001073 WO2000034281A1 (fr) 1998-12-04 1999-12-03 Derives de methotrexate

Publications (1)

Publication Number Publication Date
CA2353839A1 true CA2353839A1 (fr) 2000-06-15

Family

ID=3811723

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002353839A Abandoned CA2353839A1 (fr) 1998-12-04 1999-12-03 Derives de methotrexate

Country Status (9)

Country Link
EP (1) EP1135390A1 (fr)
JP (1) JP2002531566A (fr)
KR (1) KR20010081050A (fr)
CN (1) CN1334815A (fr)
AU (1) AUPP751398A0 (fr)
CA (1) CA2353839A1 (fr)
NO (1) NO20012720L (fr)
WO (1) WO2000034281A1 (fr)
ZA (1) ZA200104533B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1958632A1 (fr) * 2007-02-14 2008-08-20 Dan Stoicescu Utilisation de dérivés de la pyrimidine condensés pour le traitement de maladies inflammatoires et autoimmunes
CN101926860A (zh) * 2010-05-07 2010-12-29 宁波立华制药有限公司 一种芍药提取物甲氨蝶呤组合物及其制备方法与应用
CN110174363A (zh) * 2019-01-09 2019-08-27 北京九强生物技术股份有限公司 6-磷酸葡萄糖脱氢酶突变体及其在制备检测试剂中的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69426629T2 (de) * 1993-08-02 2001-08-02 Commw Scient Ind Res Org Therapeutische verbindung - fettsäurekonjugate
US5952499A (en) * 1995-01-16 1999-09-14 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound-fatty acid conjugates

Also Published As

Publication number Publication date
NO20012720D0 (no) 2001-06-01
EP1135390A1 (fr) 2001-09-26
AUPP751398A0 (en) 1999-01-07
KR20010081050A (ko) 2001-08-25
NO20012720L (no) 2001-07-31
WO2000034281A1 (fr) 2000-06-15
JP2002531566A (ja) 2002-09-24
ZA200104533B (en) 2002-06-03
CN1334815A (zh) 2002-02-06

Similar Documents

Publication Publication Date Title
US6221881B1 (en) Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
EP2347770B1 (fr) Procédé de production d' une préparation pharmaceutique injectable
EP0116208B1 (fr) Analogues de mitomycine
JP6152389B2 (ja) 抗線維化化合物及びその使用
DeGraw et al. Synthesis and antitumor activity of 10-alkyl-10-deazaminopterins. A convenient synthesis of 10-deazaminopterin
JP2003514770A (ja) 抗増殖性医薬の燐脂質プロドラッグ
WO1998014468A1 (fr) Composes glyco-conjugues de derives de camptothecine modifies (liaison a un cycle a ou b)
EP1062209B1 (fr) Antifoliques anti-inflammatoires et antitumoraux metaboliquement inertes
US6207673B1 (en) Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
JP2002501512A (ja) 葉酸アンタゴニストと担体とを含有してなるコンジュゲート
Rosowsky et al. Methotrexate analogues. 25. Chemical and biological studies on the γ-tert-butyl esters of methotrexate and aminopterin
ES2868180T3 (es) Derivados de pirido-imidazo rifamicina como agentes antibacterianos
EP0537492A2 (fr) Sels stables de l'acide 5,10-méthylènetétrahydrofolique
CA2353839A1 (fr) Derives de methotrexate
PIGNATELLO et al. Aliphatic α, γ‐bis (Amides) of Methotrexate. Influence of Chain Length on In‐vitro Activity Against Sensitive and Resistant Tumour Cells
Nair et al. Folate analogs. 22. Synthesis and biological evaluation of two analogs of dihydrofolic acid possessing a 7, 8-dihydro-8-oxapterin ring system
Roth et al. 2, 4-Diamino-5-benzylpyrimidines and analogs as antibacterial agents. 9. Lipophilic trimethoprim analogs as antigonococcal agents
EP0096870A1 (fr) Esters du métronidazole avec la N,N-diméthylglycine et ses sels d'addition d'acides
EP0388456A1 (fr) Derives de l'acide 8,10-dideazatetrahydrofolique
AU1761500A (en) Methotrexate derivatives
CA3146510A1 (fr) Derives de camptothecine ayant une fraction disulfure et une fraction piperazine
Kobayashi et al. Disposition and metabolism of KW-2149, a novel anticancer agent
US11129899B1 (en) Methotrexate derivatives and uses thereof
WO2023078230A1 (fr) Intermédiaire conjugué anticorps-médicament comprenant sn38 et procédé de préparation associé
Nair et al. Folate analogs altered in the C9-N10 bridge region. 16. Synthesis and antifolate activity of 11-thiohomoaminopterin

Legal Events

Date Code Title Description
FZDE Discontinued